119 related articles for article (PubMed ID: 17879531)
1. [Effects of Migu Tablet on bone mineral density, serum levels of osteoprotegerin and its ligand and bone metabolic markers in patients with postmenopausal osteoporosis].
Dai Y; Shen L; Yang YP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Aug; 27(8):696-9. PubMed ID: 17879531
[TBL] [Abstract][Full Text] [Related]
2. [Effects of Migu tablet on bone mineral density, serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis].
Dai Y; Shen L
Zhongguo Zhong Yao Za Zhi; 2007 Nov; 32(22):2409-12. PubMed ID: 18257271
[TBL] [Abstract][Full Text] [Related]
3. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
4. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
5. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
7. The association of serum osteoprotegerin and osteoporosis in postmenopausal hemodialysis patients: a pilot study.
Wu WT; Lee RP; Wang CH; Fang TC; Lin NT; Chen IH; Hsu BG
J Womens Health (Larchmt); 2010 Apr; 19(4):785-90. PubMed ID: 20210559
[TBL] [Abstract][Full Text] [Related]
8. [Age-related and menopause-related changes of urinary excretion of C- and N-terminal cross-linked telopeptides of type I collagen and the relationships thereof with menopause-related bone loss].
Liu SP; Liao EY; Wu XP; Cao XZ; Shan PF; Su X
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):371-5. PubMed ID: 16677543
[TBL] [Abstract][Full Text] [Related]
9. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Fernández-García D; Muñoz-Torres M; Mezquita-Raya P; de la Higuera M; Alonso G; Reyes-García R; Ochoa AS; Ruiz-Requena ME; Luna JD; Escobar-Jiménez F
J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
[TBL] [Abstract][Full Text] [Related]
10. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
11. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
[TBL] [Abstract][Full Text] [Related]
12. [Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients].
Zhang XZ; Song LG; Li H; Han JF; Qian GF; He M; Li Y; Gu L
Zhonghua Nei Ke Za Zhi; 2006 Jul; 45(7):565-8. PubMed ID: 17074112
[TBL] [Abstract][Full Text] [Related]
13. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
14. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
[TBL] [Abstract][Full Text] [Related]
15. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Sewerynek E; Król I; Stępień-Kłos W; Jędrzejczyk S
Endokrynol Pol; 2016; 67(2):174-84. PubMed ID: 26884284
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study on treatment of postmenopausal osteoporosis by Yigu capsule].
Zhang RH; Chen KJ; Lu DX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Aug; 24(8):680-4. PubMed ID: 15366587
[TBL] [Abstract][Full Text] [Related]
17. [Age-related change of bone biochemical markers and their relationships to mineral density in healthy Chinese men].
Zhao Q; Shen LX; Zhang H; Wu XP; Xie H; Shan PF; Cao XZ; Liao EY; Luo XH
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1957-61. PubMed ID: 17064589
[TBL] [Abstract][Full Text] [Related]
18. [Effect of osteoprotegerin gene polymorphism on bone mass in postmenopausal women].
Cheng Q; Zhu HM; Miao YX; Zhu XY; Chen XP; Zhang XM
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):274-7. PubMed ID: 15059506
[TBL] [Abstract][Full Text] [Related]
19. [The relationships between biomarkers of age-related changes in bone turnover and bone mineral density in healthy Chinese women].
Liu H; Liao EY; Wu XP; Zhang H; Luo XH; Xie H; Cao XZ; Liu SP
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):805-9. PubMed ID: 15634535
[TBL] [Abstract][Full Text] [Related]
20. The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.
Hooshmand S; Brisco JR; Arjmandi BH
Br J Nutr; 2014 Jul; 112(1):55-60. PubMed ID: 24780728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
